Quick Information
- Category:
- Healthcare
- Pricing:
- Contact Sales
- Platforms:
- Web, Cloud
- Free Plan:
- No
- Last Verified:
- October 2026
What Is Paige?
Paige is an AI company for pathology and cancer diagnosis. Its flagship Paige Prostate received FDA De Novo marketing authorization in 2021, reported as the first for a software algorithm that assists users in digital pathology. It later gained EU IVDR certification in 2025. Outlets sometimes say "cleared" and sometimes "authorized", and De Novo authorization is the more precise term.
Tempus agreed to buy Paige for about $81 million, paid mostly in stock and including Paige's remaining Microsoft Azure commitment. Tempus was reportedly interested in a dataset of nearly seven million digitized pathology slides plus clinical data licensed from Memorial Sloan Kettering. Since the deal Tempus has launched Paige Predict, built on Paige's foundation model, covering 123 molecular biomarkers and oncogenic pathways across 16 cancer types. Tempus' chief executive has noted that reimbursement for digital pathology algorithms has lagged, which may slow adoption. Paige does not publish prices, and the tools are sold to labs and health systems on custom terms.
Paige fits pathology labs and health systems building digital pathology workflows, and biopharma teams that need biomarker prediction from slides. Related tools include PathAI, Tempus and Lunit. Browse the Healthcare tools directory for more.
What Can You Use Paige For?
Prostate cancer detection
Paige Prostate assists pathologists reviewing biopsies.
Biomarker prediction
Paige Predict estimates molecular biomarkers from slides.
Digital pathology research
A large slide dataset supports model development.
Paige Features
- Paige Prostate — FDA De Novo authorized (2021) and IVDR certified (2025).
- Paige Predict — Covers 123 biomarkers and pathways across 16 cancer types.
- Foundation model — Built on a large digitized slide dataset.
- Tempus integration — Now part of Tempus' diagnostics and data business.
Who Is Paige For?
- Pathology labs — Want regulatory-grade AI for prostate biopsies.
- Biopharma and research teams — Use biomarker prediction in trials.
Paige Pros & Limitations
What We Like
- First FDA De Novo authorized AI in digital pathology
- EU IVDR certification for Paige Prostate
- Backed by Tempus and a very large slide dataset
Limitations
- No public pricing
- Reimbursement for digital pathology AI has lagged
- Product roadmap now depends on Tempus
Paige Pricing
| Plan | Price | Main Features |
|---|---|---|
| Enterprise | Custom | Paige Prostate, Paige Predict and related pathology AI |
Pricing was last verified October 2026. Check the official website for the latest pricing.
AI Listing Jungle Ranking
- Global Rank:
- #64
- Overall Score:
- 86.6/100
- Monthly Users:
- –
- Rank Change:
- ▼ 19
This ranking reflects AI Listing Jungle's own independent scoring methodology and is not an endorsement by Paige or its company. How Our Rankings Work
Frequently Asked Questions
Is Paige Prostate FDA authorized?
Yes, it received FDA De Novo marketing authorization in 2021.
Who owns Paige?
Tempus acquired Paige for about $81 million.
What is Paige Predict?
A Tempus product built on Paige's foundation model, covering 123 biomarkers in 16 cancer types.
How much does Paige cost?
Pricing is not public.
Our Take
Paige has one of the strongest regulatory records in pathology AI, and Tempus gives it scale and data.
Budget for integration work and check reimbursement before rollout.
Paige Alternatives
Paige Comparisons
Ready to try Paige?
Visit the official website to get started.
Visit Official WebsiteAI Listing Jungle is an independent AI tools directory. Product names, logos, and trademarks belong to their respective owners.